The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 29, 2019

Filed:

Mar. 23, 2015
Applicants:

Academisch Medisch Centrum, Netherlands, NL;

Universiteit Leiden, Netherlands, NL;

Inventors:

Herman Steven Overkleeft, Netherlands, NL;

Stan Van Boeckel, Netherlands, NL;

Johannes Maria Franciscus Gerardus Aerts, Netherlands, NL;

Amar Ghisaidoobe, Netherlands, NL;

Richard Van Den Berg, Netherlands, NL;

Assignees:

ACADEMISCH MEDISCH CENTRUM, Amsterdam, NL;

UNIVERSITEIT LEIDEN, Leiden, NL;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 211/14 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 211/40 (2006.01);
U.S. Cl.
CPC ...
C07D 211/40 (2013.01);
Abstract

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group ('X') on the methyloxy-carbon. These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and/or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.


Find Patent Forward Citations

Loading…